Parkinson's Disease : From Genetics to Clinical Practice by Clarimón, Jordi et al.
Send Orders for Reprints to reprints@benthamscience.net 
560 Current Genomics, 2013, 14, 560-567  
 
Parkinson's Disease: From Genetics to Clinical Practice 
Jordi Clarimón* and Jaime Kulisevsky 
Neurology Department, Institut d’Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de 
Barcelona, Barcelona, Spain, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas 
(CIBERNED), Madrid, Spain 
Abstract: Breakthroughs in genetics over the last decade have radically advanced our understanding of the etiological ba-
sis of Parkinson's disease (PD). Although much research remains to be done, the main genetic causes of this neurodegen-
erative disorder are now partially unraveled, allowing us to feel more confident that our knowledge about the genetic ar-
chitecture of PD will continue to increase exponentially. How and when these discoveries will be introduced into general 
clinical practice, however, remains uncertain. In this review, we provide a general summary of the progress in the genetics 
of PD and discuss how this knowledge will contribute to the diagnosis and clinical management of patients with, or at risk 
of this disorder. 
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INTRODUCTION 
 Dissection of the genetic architecture of any complex 
disorder like Parkinson's disease (PD) is paramount to under-
standing its biological basis, assess the individual predisposi-
tion of disease, and evaluate the capacity of novel therapeu-
tic interventions in early, even pre-symptomatic stages. A 
striking progress in genetics of PD during the last decade has 
led to the identification of a substantial number of Mendelian 
genes and loci, as well as a large list of genes with signifi-
cant effects on disease risk. In order to make an apprehensi-
ble description of what has been discovered during the last 
15 years, we have performed a summary divided into three 
main topics: Mendelian genes, well established genes related 
to sporadic forms of disease, and genes with low risk effects 
resulting from genome-wide association analyses. We also 
discuss the usefulness and limitations of genetic testing. 
1. MENDELIAN GENES 
PARK1 (PARK4): -Synuclein; Chromosome 4q21-23 
 Three missense mutations (p.A30P, p.E46K, and 
p.A53T) in the gene encoding for -synuclein (SNCA), the 
main protein that aggregates in Lewy bodies, have been re-
ported in families with autosomal dominant forms of PD [1]. 
Broadly, these point mutations range from a relatively typi-
cal levodopa-responsive PD to a disorder reminiscent of dif-
fuse Lewy body dementia, with a relatively early age at onset 
(mean age of 45 years). In 2003, a genomic triplication of 
1.5 million base-pairs that includes the entire SNCA gene 
was found to segregate with disease in a large family called 
the "Iowa kindred" [2, 3]. Additional families with either 
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SNCA triplication or duplication mutations were later dis-
covered [4, 5]. In these cases, the -synuclein gene is normal 
in sequence but abnormal in dose. Interestingly, duplication 
of the SNCA locus more closely resembles idiopathic PD, 
whereas patients with four copies of the gene tend to present 
an earlier onset and a more aggressive clinical course, in-
cluding cognitive decline and shorter survival. 
PARK2: Parkin; Chromosome 6q5.5-q27 
 Mutations in PARK2 are the leading cause of autosomal 
recessive early-onset PD. They account for up to 10% of 
patients with PD onset before 50 years [6, 7] and as high as 
77% of patients with onset at 20 years or younger [8]. Since 
PARK2 was identified in 1998, a wide variety of mutations, 
including exon rearrangements, single base pair substitu-
tions, and small deletions or insertions of one or several base 
pairs, have been identified in nearly all populations studied, 
regardless of ethnic origin. Patients with mutations present a 
clinical syndrome that is indistinguishable from that of idio-
pathic PD, with a good response to levodopa. Brain autopsy 
studies in PARK2 cases have shown pathological heteroge-
neity. Although the majority of reported cases present sub-
stantia nigra degeneration without neuronal inclusions of 
alpha-synuclein [9-11], other patients have been described 
with Lewy bodies (LB) in the nigra and locus coreuleus [12], 
basophilic LB-like inclusions in the pedunculopontine nu-
cleus [13], or neurofibrillary tangle pathology in the cerebral 
cortex and brainstem nuclei [14]. 
 Interestingly, carriers of heterozygous PARK2 mutations 
are at risk to develop PD [15-17], and some coding poly-
morphisms appear to be risk factors for sporadic and familial 
PD [18]. The role of heterozygous PARK2 mutations as a PD 
risk factor has been supported by positron emission tomo-
graphy (PET) scanning studies showing preclinical changes 
in striatal structures in asymptomatic heterozygous mutation 
carriers [19, 20]. 
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PARK6: PINK1; Chromosome 1p36 
 PTEN-induced putative kinase 1 gene (PINK1) is the 
second most frequent causative gene in early onset autoso-
mal recessive PD. Homozygous and compound heterozygous 
mutations comprising nonsense, missense and small dele-
tions, have been described in patients with a slowly progres-
sive levodopa-responsive phenotype. Intriguingly, several 
alterations in imaging biomarkers have been reported in pa-
tients carrying a single PINK1 mutation. For example, a low 
uptake of the tracer iodine-123 metaiodobenzylguanidine in 
myocardial muscle [21], and a 20 to 30% reduction in cau-
date and putamen F-dopa have been shown in PINK1 muta-
tion carriers [20]. Nonetheless, there is no clear evidence that 
PINK1 heterozygosity increases susceptibility to idiopathic 
PD [22]. 
PARK7: DJ1; Chromosome 1p36 
 Homozygous and compound heterozygous mutations in 
DJ1 are rare causes of early onset PD with a recessive inheri-
tance [23]. Although patients with DJ1 mutations present a 
clinical picture of idiopathic PD with L-dopa responsiveness, 
three cases from the same family have been reported to have 
a phenotype comprising early-onset parkinsonism, dementia, 
and amyotrophic lateral sclerosis [24].  
PARK8: LRRK2; Chromosome 12p11.2-q13.1 
 The most frequently mutated gene in PD is the gene en-
coding for the Leucine-rich repeat kinase 2 (LRRK2) [25, 
26]. Mutations in this gene lead to an autosomal dominant 
PD with onset in the sixth decade of life. Although more 
than 250 aminoacid substitutions have been reported in this 
gene [27], genetic evidence for pathogenicity by cosegrega-
tion with disease within families has only been proven for 
six variants: p.R1441C, p.R1441G, p.R1441H, p.Y1699C, 
p.G2019S, and p.I2020T. Among these mutations, p.G2019S 
is the most common, with a worldwide frequency ranging 
from 1% of patients with sporadic PD to 4% of patients with 
familial PD. These frequencies vary in different populations, 
however. It is present in ~40% of North African Berber Ar-
abs with PD, in 28% of Ashkenazi Jews with hereditary dis-
ease (and in 10% with sporadic disease), and in less than 
0.1% of Asians [28]. The age-related penetrance of the 
p.G2019S mutation has been estimated to be 28% at 59 
years, 51% at 69 years, and 74% at 79 years. Patients harbor-
ing the p.G2019S mutation are clinically indistinguishable 
from those with idiopathic PD. Nonetheless, mutation carri-
ers can present a more benign progression and less preva-
lence of dementia during the course of PD course than non-
carriers. 
PARK9: ATP13A2; Chromosome 1p36 
 A syndrome appearing at very young ages, between 11 
and 16 years, was first described in 1994 in a consanguine-
ous Jordanian family originating from a small community 
named Kufor-Rakeb [29]. This form of the disease consists 
of akinetic-rigid parkinsonism with concomitant bradykine-
sia, progressive spasticity, supranuclear upgaze paresis and 
dementia. It has a good response to L-dopa. The gene was 
mapped to the short arm of chromosome 1 (1p36) in 2001 
[30], and the responsible gene (ATPase type 13A2, ATP 
13A2) was cloned soon afterwards [31]. Since then, few 
families have been described worldwide and mutations in 
ATP13A2 seem to be a very rare cause of Parkinsonism. 
PARK14: PLA2G6; Chromosome 22q13.1 
 Mutations in the PLA2G6 gene, encoding for the phos-
pholipase A2, group VI (cytosolic, calcium-independent) 
gene, typically lead to a recessive degenerative disorder 
characterized by motor and cognitive regression starting at 
the first or second year of life [32]. Cerebellar cortical atro-
phy and basal ganglia iron accumulation are prominent radi-
ologic features in these patients, and spasticity, dystonia and 
cerebellar features are also evident in mutation carriers [33]. 
It is important to note that patients with homozygous 
PLA2G6 mutations can also present with adult-onset 
levodopa-responsive complicated parkinsonism without 
brain iron accumulation on MRI. However, a clinical pheno-
type comprising slowly progressive gait problems, cognitive 
decline, clumsiness, hand tremor, bradykinesia, dysarthria 
and dystonia has also been described [34].  
PARK15: F-box protein 7; Chromosome 22q12-q13 
 Pyramidal signs with an onset within the third decade of 
life, followed by L-dopa responsive extrapyramidal symp-
toms, were first described in a large Iranian family with an 
autosomal recessive pattern of inheritance [35]. The authors 
cloned the FBXO7 gene as the genetic cause of this disorder. 
A handful of families with early-onset, progressive parkin-
sonism with associated pyramidal tract signs due to FBXO7 
homozygous and compound heterozygous mutations have 
since been reported in Italy, Turkey, the Netherlands and 
Pakistan [36, 37]. Clinical features such as bulbar signs, su-
pranuclear gaze palsy and cognitive deterioration have been 
reported in some of these families, expanding the heteroge-
neity related to FBXO7 mutations. 
PARK17: VPS35; Chromosome 16q12 
 The recent finding of VPS35 is a good example of how 
targeted enrichment of genomic DNA and next-generation 
sequencing are powerful tools for the discovery of Men-
delian genes. This gene encodes for the vacuolar protein 
sorting 35 homolog (S. cerevisiae), and is the causal gene for 
some forms of late-onset, autosomal dominant PD. The gene 
was found in 2011, when two independent groups performed 
a caption of the ~180,000 exons that represent 22,000 genes 
of the human genome and sequenced all the resulting frag-
ments by means of next generation sequencing systems in 
families with autosomal dominant PD from Switzerland and 
Australia [38, 39]. A missense mutation (p.D620N) in the 
VPS35 gene was found in both families. Subsequent analyses 
disclosed families from Tunisia, Israel and Austria carrying 
the same mutation. Although other missense mutations were 
found by both groups, the pathogenicity of these additional 
mutations remains unknown. 
2. SNCA, GBA AND MAPT AS WELL ESTABLISHED 
GENES RELATED TO PD 
SNCA Genetic Variation and PD Risk 
 In 1999, certain alleles of the polymorphic complex re-
peat site NACP-Rep1 (D4S3481), which is composed of a 
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mixed length of contiguous dinucleotides, and located 
~10Kilobases upstream of the transcriptional start site of the 
SNCA gene, were associated with an increased risk of spo-
radic PD [40]. Subsequent analyses trying to replicate this 
finding were not always successful. In 2006 however, a large 
study that included 2,692 PD cases and 2,652 controls and 
incorporated previous analyses but also added novel data 
revealed compelling evidence that NACP-Rep1 was associ-
ated to PD risk [41]. The biological link between this micro-
satellite and PD has been supported to some degree by func-
tional data, which suggest that -synuclein levels could be 
influenced by NACP-Rep1 alleles through a regulation of 
SNCA gene transcription [42]. The role of SNCA in sporadic 
forms of PD has been fueled by different genome-wide asso-
ciation studies. These analyses indicate that common 
polymorphisms located downstream of the gene (more than 
125 Kb away from the NACP-Rep1 microsatellite) might 
also contribute to PD risk [43-45]. Whether the NACP-Rep1 
variant, located upstream of SNCA, or biallelic polymor-
phisms located downstream of the gene are independent as-
sociation signals is still a matter of controversy [46, 47]. 
GBA Mutations and PD Risk 
 Homozygous mutations in the glucocerbrosidase (GBA) 
gene lead to Gaucher disease, the most common lysosomal 
storage disorder. The presence of progressive parkinsonian 
features in some patients with Gaucher disease was a key 
element in identifying mutations in GBA as an important risk 
factor for PD. Since the first discovery that resulted from the 
analysis of Ashkenazi Jewish patients, [48] many studies 
worldwide have replicated this finding [49-54]. In 2009, a 
multicentric international analysis that included 5,691 pa-
tients and 4,898 controls indicated that GBA mutations may 
be present in 3%-10% of PD patients from a non-Ashkenazi 
Jewish origin, and carriers of a GBA mutations have a five-
fold increased risk to develop PD compared to noncarriers 
[55]. The clinical phenotype associated to a GBA mutation is 
indistinguishable from idiopathic PD. However, bradykine-
sia, resting tremor, rigidity and symmetric onset have been 
reported to be more frequent features in patients carrying a 
GBA mutant allele. A remarkable characteristic in patients 
harboring a GBA risk allele is the greater prevalence of cog-
nitive decline and dementia during PD course [52, 56, 57], 
and carriers might have a six-fold increased risk to dementia 
compared to noncarriers [58]. 
MAPT H1 Haplotype and PD Risk 
 In 2002, the first genetic association between MAPT H1 
halpotype (an extended haplotype that results from a com-
mon genomic inversion of approximately 800 kb in the large 
arm of chromosome 17 containing the MAPT gene) and PD 
risk was reported through a limited number of cases and con-
trols [59]. With more than 20 studies performed to date, 
MAPT seems to be undoubtedly associated with PD risk in 
populations with European ancestry but not in Asians 
(http://www.pdgene.org) [60]. The MAPT H1 haplotype is 
present in all human populations, whereas the inverted 
haplotype (named H2) is mainly found in southwest Asian 
and southern European populations, with frequencies rang-
ing from 21% to 32% [61, 62]. Interestingly, a longitudinal 
study performed in 2003 revealed that PD patients with the 
H1 variant followed for 3.5 years had a greater risk of cogni-
tive decline than noncarriers [63]. A subsequent comprehen-
sive analysis from same authors concluded that the MAPT 
H1 variant was the strongest independent predictor of de-
mentia among PD patients, with an odds ratio of 12 over 5 
years of follow-up [64]. Data originated in our and other's 
centers have provided compelling evidence that the MAPT 
H1 variant leads to an increased risk of cognitive decline and 
dementia in PD patients [65-67]. 
3. GENES WITH LOW RISK EFFECTS: RESULTS 
FROM GENOME WIDE ASSOCIATION STUDIES 
(GWAS) 
 In 2005 the first genome-wide association study of PD 
was performed in 443 sibling pairs discordant for PD, and a 
second tier of 332 patients and controls [68]. In 2006 a sub-
sequent study that included 537 samples was not able to rep-
licate previous findings and proposed that there are no com-
mon genetic variants with high risk effects on PD [69]. 
Three years later, two studies from Japan and Europe used 
more powerful sample sizes that evidenced the association 
with SNCA, MAPT, LRRK2, and disclosed novel loci in 
chromosome 1 (PARK16) and chromosome 4p15 (close to 
the BST1 gene) [70, 71]. In that same year, a similar study 
comprising 857 PD patients with a family history of PD and 
a similar number of controls disclosed a 112 kb region on the 
short arm of chromosome 4 that contained the genes GAK 
and DGKQ [72]. Additional analyses with similar sample 
sizes combined with data released from previous studies 
supported these genetic associations, [73-76] and yielded 
novel loci, like the human leukocyte antigen (HLA) region in 
choromosme 6p21.3 (which was designated PARK18) [74, 
75]. In 2011 a meta-analysis of datasets from five PD 
GWAS was conducted by the International Parkinson's Dis-
ease Genomics Consortium (IPDGC). This study, which 
included a discovery phase with 5,333 cases and 12,019 con-
trols, and a replication phase consisting of 7,053 cases and 
9,007 controls, revealed five novel loci (ACMSD, STK39, 
MCC1/LAMP3, SYT11, and CCDC62/H1P1R) with subtle 
but significant risk effects [45]. A follow-up analysis per-
formed by the same consortium revealed five additional PD 
risk loci that comprised the previously detected region in 
chromosome 1q32 (PARK16) and variants located close to 
the genes STBD1, GPNMB, FGF20, and STX1B [77]. To-
gether with this study, an analysis performed by the Personal 
genetics company 23andMe, that incorporated over 3,400 
cases and 29,000 controls, confirmed the outcomes from the 
IPDGC and yielded significant signals near SREBF1/RAI1 
and SCARB2 genes [43]. Most recently, a meta-analysis was 
performed from data at the freely available online database 
"PDGene" (http://www.pdgene.org), which contains a com-
prehensive collection of all public genetic association studies 
performed on PD. It confirmed the existence of eleven loci 
previously shown to increase or decrease PD risk and re-
vealed a novel association with an intronic polymorphism in 
ITGA8 gene on chromosome 10p13 [44].  
4. MOLECULAR GENETIC TESTING 
 Up to 40% of PD patients with age at onset of less than 
30 years and 17% of those with age at onset of less than 50 
yeas will probably have a mutation in one of the known 
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Mendelian genes linked to PD [78]. Therefore, genetic testing 
for diagnostic purposes in families with a Mendelian aggrega-
tion of disease is a very powerful tool and may be appropriate 
in many instances. Due to the increasing number of genes re-
lated to PD, genetic diagnostic process can be long, expensive 
and complex using classic Sanger-based sequencing ap-
proaches. The advent of next-generation sequencing (NGS) 
tools will allow a rapid, efficient and cost-effective process to 
test for genetic alterations in genetic forms of PD. Implement-
ing NGS in diagnostic services, however, can be challenging. 
First, the large amount of data resulting from NGS can com-
plicate the interpretation of pathogenic variants. Second, large 
gene dosage alterations (such as deletions and insertions) can 
be missed with NGS technologies. Finally, genomic regions 
with enriched G-C stretches are typically poorly captured and 
therefore mutations within these regions could be omitted. In 
any case, although genetic testing can be conducted in a suc-
cessful and widely available manner, they should be per-
formed in a multidisciplinary setting supported by personnel 
with expertise in this area. The reason for this multifaceted 
approach in genetic counseling is the possible ethical, social, 
psychological and legal consequences of a potential positive 
result from the test. 
 Genetic counseling and risk evaluation in sporadic, late 
onset PD, however, is likely of limited clinical utility at the 
present time. Predictive accuracy is poor due to the small 
effect sizes of genetic variants that have been associated with 
PD risk. As most of these genetic variants only explain a 
small proportion of the disease (Fig. 1), caution should be 
taken when interpreting this kind of genetic data for counsel-
ing purposes. 
 The determination of genetic causes contributing to the 
modification of disease (modifier genes) is of extraordinary 
importance in terms of clinical follow up and management. 
GBA mutation or MAPT H1 allele status, for example, might 
be an independent risk factor for cognitive impairment in 
patients with PD and could therefore have strong implica-
tions in the disease course and therapeutic treatments [52, 
56, 58, 64, 65].  
 Further insights into the genetic causes of PD are war-
ranted, and an overwhelming amount of new data will 
probably come to light in coming years. How these data are 
handled in terms of genetic counseling and therapeutic inter-
ventions is a major responsibility that governments, scien-
tists, the biotechnology industry, and civil society must ap-
proach with sensitivity, objectivity and rigor. 
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